Effect Of Acupoint Application Therapy On Patient With Persistent Bronchial Asthma And Serum IL-33

PurposeIn order to evaluate the clinical efficacy of Acupoint Application in the treatment of patients with chronic persistent asthma by serum IL-33 level,lung function,asthma symptom control scale(ACT^TM),asthma quality of life scale（AQLQ）and other indicators,hoping to find an effective and affordable bronchial asthma control method combining traditional Chinese and Western medicine.MethodAccording to the Inclusion criteria and Exclusion criteria,40 patients with chronic persistent asthma who used formoterol/budesonide compound inhalation preparation in the respiratory department of our hospital were randomly divided into two groups according to age and gender.One group was the experimental group,and the other group was the control group.The experimental group was treated with Acupoint application Therapy+formoterol/budesonide compound inhalation.The control group was treated with compound inhaled drug.After the trial,the levels of serum IL-33,lung function,ACT^TM score and AQLQ score were compared between the two groups.Result1.There are 40 patients who met the inclusion criteria were Participated in this study,20cases in each group.There was no significant difference in gender,age,height,weight,baseline level of pulmonary function（FEV1）and course of disease between the two groups（P<0.05）.2.The level of serum IL-33 in the experimental group before and after treatment was statistically significant（P<0.05）;the level of serum IL-33 in the control group before and after treatment was not statistically significant（P>0.05）;there was statistical difference between the two groups before and after treatment（P<0.05）.3.The pulmonary function（FEV1,FVC,FEV1/FVC,FEV1%pred,FVC%pred,PEF,FEF25%pred）of the experimental group at the 12th week was significantly different from that before treatment（P<0.05）,among which FEV1,FVC,FEV1/FVC,FEV1%pred,FVC%pred,FEF25%pred at the 4th and 8th week were significantly different from those before treatment（P<0.05）;PEF at the 8th week was significantly different from that before treatment（P<0.05）).In the control group,FEF75%pred at the 4th,8th and 12th week was significantly different from before treatment（P<0.05）;FEV1/FVC,FEV1%pred and FEF25%pred at the4th week were significantly different from those before treatment（P<0.05）,but there was no significant difference at the 8th and 12th week from those before treatment（P>0.05）;PEF at the 4th week and 8th week was statistically significant from that before treatment（P<0.05）,the 12th week compared with before treatment was not statistically significant（P>0.05）.4.There was no significant difference in ACT^TMscore between the two groups at each follow-up time point（P>0.05）,and there was no significant difference between the two groups at each follow-up time point and before treatment（P>0.05）.There was no significant difference in the total AQLQ score between the two groups at the time of entering the group,the 4th week,the 8th week and the 12th week（P>0.05）.There was no significant difference in the 4th week,the 8th week and the 12th week between the control group and before treatment（P>0.05）.There was significant difference Activity limitation score at the 8th week and the12th week between the experimental group and before treatment（P<0.05）Conclusion1.Acupoint application Therapy can reduce the level of serum IL-33 in patients with chronic duration asthma.2.Acupoint application Therapy can improve lung function（FEV1,FVC,FEV1/FVC, FEV1%pred,FVC%pred）3.There was no significant change in asthma control level between the two groups before and after treatment.4.Acupoint application Therapy can improve the quality of life of asthma patients by reducing the degree of activity limitation.